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Expression of nNOS mRNA was found in normal human and mouse skin tissue. Upon wounding, we observed a
rapid downregulation of nNOS mRNA and protein in wounds of mice; however, when repair continued, nNOS mRNA
was strongly upregulated and nNOS protein expression peaked at late stages of healing. Immunohistochemistry
revealed wound keratinocytes as the cellular source of nNOS. In line with the in vivo situation, we found a basal
expression of nNOS in the human keratinocyte cell line HaCaT. A marked stimulation of nNOS expression in the
cells was achieved with epidermal growth factor receptor (EGFR) ligands such as epidermal growth factor (EGF),
heparin-binding EGF, transforming growth factor-a and two alternate splicing forms of the neuregulin gene. EGF-
induced induction of nNOS was completely inhibited by the speciﬁc EGFR antagonist PD153035 and by the EGFR
and Janus kinase 2/3 inhibitor AG490. Activation of EGFR might contribute to the observed upregulation of nNOS
also in skin repair, as we found a spatial and temporal correlation of phosphorylated EGFR (Y1173) with nNOS expres-
sion at the wound site. Thus, in addition to the inducible- and endothelial-type NOS isoforms, also nNOS expression
is regulated in the process of cutaneous wound repair.
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Nitric oxide (NO) is now well established as an important
messenger molecule that is involved in physiological and
pathophysiological processes in numerous organ systems.
A variety of different cell types are able to release NO, which
can be synthesized by three distinct nitric oxide synthase
(NOS) isoforms: the neuronal (nNOS), the inducible (iNOS),
and the endothelial (eNOS) isoform (Moncada et al, 1991;
Fo¨rstermann et al, 1994; Alderton et al, 2001).
NO has been shown to play important roles in normal
skin biology and also diseased skin (Bruch-Gerharz et al,
1998a, b; Weller, 1999; Frank et al, 2002). Constitutively
expressed, eNOS and iNOS have been initially reported in
keratinocytes from normal skin (Shimizu et al, 1997). Studies
on skin tissue have also demonstrated a key function of NO
in the process of cutaneous wound healing (Frank et al,
2002). A crucial role for iNOS enzymatic activity during the
repair process was suggested, as iNOS-deficient mice
suffered from a delay in wound repair (Yamasaki et al, 1998),
and as inhibition of iNOS during healing resulted in a
markedly reduced re-epithelialization (Stallmeyer et al,
1999). In line, an early induction of iNOS upon wounding
has been well documented (Frank et al, 1998a, b).
It is now established that expression of human nNOS is
not restricted to neuronal cells. Interestingly, recent studies
have demonstrated the expression of the neuronal isoform
also in skin-derived cell types such as keratinocytes and
melanocytes (Baudouin and Tachon, 1996; Romero-Graillet
et al, 1996; Ormerod et al, 1998). Moreover, nNOS-derived
NO has been shown to be involved in the modulation of
skin proliferation and melanogenesis (Romero-Graillet et al,
1997).
Initially, the nNOS protein was considered to be
constitutively expressed; however, more recent evidence
demonstrated that expression of the nNOS gene can be
regulated by a variety of physiological and pathological
stimuli (Dawson et al, 1998; Fo¨rstermann et al, 1998).
Accordingly, the human nNOS gene exhibits a complex
expressional regulation, with multiple nNOS mRNA species
produced in a tissue-specific and developmentally regu-
lated manner (Wang et al, 1999; Saur et al, 2002; Boissel
et al, 2003). In this study, we investigated the presence and
potential regulation of nNOS mRNA and protein expression
in skin repair. Interestingly, we found the nNOS isoform
expressed in keratinocytes at the wound site. Moreover,
in vitro studies on keratinocytes showed that upregulation
of nNOS expression was restricted to stimulation of the
epidermal growth factor receptor (EGFR). Thus, our data
suggest an expression of nNOS in the epithelial compart-
ment during skin repair that is most likely under control of
EGFR-directed signaling pathways.
Abbreviations: EGF, epidermal growth factor; eNOS, endothelial
nitric oxide synthase; HB-EGF, heparin-binding epidermal growth
factor; iNOS, inducible nitric oxide synthase; nNOS, neuronal nitric
oxide synthase; NO, nitric oxide; NOS, nitric oxide synthase; TGF,
transforming growth factor
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Results
Expression of nNOS mRNA in human tissues and
cells RT-PCR analyses for nNOS-specific mRNA species
using different human tissues demonstrated that expression
of the nNOS gene was not restricted to neuronal tissue
(Fig 1). Amplicons represented processed nNOS transcripts,
as the primers were located in exon 13 and exon 15 of the
genomic sequence (Fig 1a). Interestingly, processed nNOS
mRNA was also found in human skin biopsies and also
human primary keratinocytes and the human keratinocyte
cell line HaCaT (Fig 1b).
Differential expression of nNOS mRNA and protein
during skin repair As we had detected the expression of
nNOS mRNA in skin tissue, we now investigated the
presence of nNOS mRNA and protein in a model of skin
repair in mice. As tightly controlled epithelial tissue move-
ments during skin regeneration were associated with an
undisturbed expression of the inducible (Frank et al, 1999;
Stallmeyer et al, 1999; Ka¨mpfer et al, 2003) and endothelial
(Stallmeyer et al, 2002) NOS isoenzymes, we determined
expression patterns of the neuronal-type NOS isoform in
normal skin and in skin after injury in mice. We isolated total
RNA and protein from full-thickness excisional wounds at
different intervals after injury and performed Real Time-PCR
or immunoblots. Sixteen wounds (for RNA) and four wounds
(for protein) from the backs of four mice were excised for
each time point. They were combined and used for RNA
or protein isolation. Normal skin from the back of non-
wounded mice was used as a control. Non-wounded skin
was characterized by a low-level expression of nNOS at the
mRNA and protein level (Fig 2a and b); however, nNOS
mRNA rapidly declined shortly after wounding (Fig 2a). As
repair moved on, interestingly, we observed a temporal
delay of the appearance of nNOS protein as compared with
expression of its mRNA. Data revealed a dramatic induction
of nNOS mRNA at day 3 post-wounding (Fig 2a), which was
not paralleled by a marked induction of nNOS protein. It is
remarkable that decreasing levels of nNOS mRNA during
later phases of repair (days 7–14) were directly correlated
with a strong increase in nNOS protein (Fig 2a and b).
Localization of nNOS expression at the wound site
Next, we directed our attention to immunolocalize the nNOS
isoform at the wound site. To do so, sections from 1, 5, and
13 d full-thickness wounds were stained with a mono-
specific, polyclonal antibody against murine nNOS protein.
At all time points, nNOS immunostaining revealed similar
expression pattern within the wound. Serial section from 5 d
is presented in Fig 3. Interestingly, nNOS was localized
at epithelial sites at the margins of the wound (Fig 3a).
Moreover, we detected an accumulation of nNOS protein
directly adjacent to the basal lamina (Fig 3a and b).
Especially, the basal keratinocytes of the migrating epithelial
were characterized by a marked expression of nNOS
protein (Fig 3c and d); however, some strongly positive
Figure 1
nNOS mRNA expression in human tissues and cells. (a) nNOS
exonic organization (exons 13–15). Arrows show the localization of the
sense and antisense primers used for PCR amplification. Exonic
localization of primers indicate that PCR amplicons (222 bp) must
represent expressed nNOS mRNA. (b) Amplifications of nNOS-specific
sequences were performed using reverse-transcribed mRNA from
human tissues and cells as indicated. nNOS, neuronal nitric oxide
synthase.
Figure2
Expression of nNOS upon skin wounding. Regulation of nNOS
mRNA (a) and protein (b) expression in BALB/c mice as assessed by
real-time PCR or immunoblot. The time after injury is indicated. Ctrl skin
represents back skin biopsies of non-wounded mice. A quantification
of nNOS mRNA (x-fold induction compared with control skin) is shown
in (a). , po0.01 (ANOVA) compared with control skin. Bars represent
mean  SD obtained from wounds (n¼48) isolated from animals
(n¼12) from three independent animal experiments. RNAs have been
equilibrated by analysis of constitutive porphobilinogen deaminase.
(b) Total protein (50 mg) from non-wounded control skin and wound
tissue was analyzed for nNOS-specific protein. A lysate from murine
brain tissue was used as to control the specificity of the used anti-
nNOS antiserum. A shorter exposure time of the immunoblot is shown
in the right panel. nNOS, neuronal nitric oxide synthase.
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cells with fibroblast-like morphology were localized within
the underlying granulation tissue (Fig 3c).
nNOS regulation in human keratinocytes (HaCaT) As we
had detected wound keratinocytes as a source of nNOS
protein expression in skin repair, we now used the human
keratinocyte cell line HaCaT as a model to determine
possible regulators of nNOS expression in vitro. As shown in
Fig 4a, keratinocytes revealed a basal expression of nNOS
mRNA (Fig 4a, left panel). As a next step, we stimulated
quiescent cells with a variety of growth factors and
cytokines. Interestingly, none of the applied growth factors
(PDGF, KGF, TGF-b1) or cytokines (IL-1b, TNF-a, IFN-g) was
able to enhance nNOS mRNA expression in the cells (data
not shown). But treatment of cells with EGF resulted in a
marked induction of nNOS mRNA levels (Fig 4a), which was
specific for the neuronal isoform of the NOS isoenzymes
(Fig 4a, middle and right panels). Stimulation (5-fold) of
nNOS mRNA by EGF peaked after 12 h and, moreover, we
detected significantly elevated levels of nNOS mRNA even
after 24 h of treatment (Fig 4b). A dose–response experi-
ment revealed that even low concentrations of EGF (1 ng
per mL) stimulated nNOS expression in HaCaT keratino-
cytes (Fig 4c). Finally, we could confirm the EGF-mediated
increase in nNOS mRNA expression at the protein level (Fig
4d). Densitometric analyses of four different blots from four
independent cell culture experiments demonstrated an
increase in nNOS protein of 270%  27% of control
(mean  SD).
Additional ligands of the ErbB network stimulate nNOS
expression As the EGFR, and the ErbB2, ErbB3, and
ErbB4 receptors constitute the EGFR family of protein
tyrosine kinases, we determined the presence of ErbB2,
ErbB3, and ErbB4 in human primary and also HaCaT
keratinocytes using RT-PCR. With exception of human
primary cells, which did not express ErbB4, we could detect
amplicons for all the other members of the EGFR family in
both keratinocyte cell types (data not shown). As the
multiplicity and redundancy of ligands for the EGFR family
is well documented (Yarden and Sliwkowski, 2001), we
speculated that additional ligands of the EGFR family might
also serve as stimulators of nNOS expression in keratino-
cytes. To this end, we treated cultured HaCaT cells with
heparin-binding EGF (HB-EGF), TGF-a, and two splice
variants of the neuregulin gene, hereregulin-a, and here-
regulin-b1. As shown in Fig 5, RNase protection assays
clearly demonstrated an upregulation of nNOS mRNA with
other ligands of the EGFR family.
Temporal and spatial correlation of activated EGFR and
nNOS at the wound site As activation of the EGFR in
keratinocytes increased the observed basal levels of nNOS
mRNA in these cells in vitro (Figs 4 and 5), we hypothesized
that we might find an activated EGFR during skin repair that
might be associated with nNOS expression with respect to
time and localization. Moreover, expression of the EGFR
has been demonstrated to be present in wounded tissue
(Stoscheck et al, 1992). First, we determined the kinetics of
activated EGFR in wound tissue. To this end, we analyzed
the immunoblots with a phospho-specific (Y-1173) antibody
against the EGFR. Not unexpected, we found a transient
increase in activated EGFR during the inflammatory and
proliferative phase of repair (Fig 6a), clearly matching the
observed induction of nNOS mRNA after wounding (Fig 2a).
But elevated levels of nNOS protein at late stages of repair
(Fig 2b) were clearly associated with declining amounts of
active EGFR (Fig 6a). Additionally, immunohistochemistry
from 5-d (Fig 6b) and 7-d (Fig 6c) wounds showed a partial
co-localization of phosphorylated EGFR in wound keratino-
cytes as compared with nNOS (Fig 3).
EGFR-mediated signaling pathways targeting nNOS
upregulation As a next step, we investigated a possible
contribution of different components of the intracellular
EGF-signaling network, that is known to originate from the
membrane-bound EGFR, to nNOS expression. To this end,
we treated HaCaT keratinocytes with EGF in the presence
or absence of several inhibitors. Samples of total cellular
RNA were subsequently analyzed by RNase protection
assay. Not unexpected, we observed a dose-dependent
inhibition of EGF-mediated nNOS expression in the pre-
sence of the specific EGFR antagonists PD153035 (Fig 7a)
and the EGFR and Janus kinase (JAK)-2/3 inhibitor AG490
(Fig 7b). Unlike the PD153035 compound, we found that
AG490 was also able to inhibit the basal expression of
nNOS in the cells (Fig 7a and b). We also tested inhibitors of
the mitogen-activated protein kinase (MAPK) pathways, but
specific MEK1,2 inhibitors (U0126 and PD98059) as well as
the inhibitor of the p38 MAPK (SB203580) had no effect on
EGF-mediated nNOS expression (data not shown). More-
over, also inhibition (Go¨6983) or activation (PDBu) of the
phospholipase C/protein kinase C pathway, or inhibition of
the PI3 kinase/protein kinase B pathway by wortmannin and
LY294002 did not alter the EGF-induced stimulation of
nNOS expression in HaCaT keratinocytes (data not shown).
Figure 3
Localization of nNOS protein in regenerating skin. Frozen sections
from mouse wounds (day 5 post-wounding) were incubated with a
polyclonal antiserum directed against nNOS. Sections were subse-
quently stained with the avidin–biotin–peroxidase complex system
using 3,3-diaminobenzidine tetrahydrochloride as a chromogenic
substrate. Nuclei were counterstained with hematoxylin. Immunoposi-
tive signals within the sections are indicated with arrows. d, dermis; e,
epidermis. nNOS, neuronal nitric oxide synthase.
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Discussion
Wound healing comprises a highly coordinated process that
leads to an at least partial reconstruction of the injured
tissue. Evidently, recent studies suggested an important
role of the short-lived mediator NO in skin repair (Frank et al,
2002). NO is synthesized from L-arginine by NOS, which
exists in three different isoforms (Moncada et al, 1991;
Alderton et al, 2001). As L-arginine represents the only
substrate for NOS activity, this enzymatic reaction links the
long-known observation that L-arginine was implicated in
wound healing (Seifter et al, 1978) with the potency of NO to
drive cutaneous repair. Although eNOS has been shown
expressed in wound margin keratinocytes upon wounding
(Stallmeyer et al, 2002), recent data from iNOS-deficient
mice identified iNOS-derived NO as a pivotal player in
wound healing (Yamasaki et al, 1998). In line, inhibition
of iNOS enzymatic activity during repair using N6- (imi-
noethyl)-L-lysine evidenced a potent effect of iNOS-derived
NO on epithelial gene expression leading to severely
impaired re-epithelialization movements (Frank et al, 1999,
2000; Stallmeyer et al, 1999). Moreover, recent data from
our laboratory showed that downregulation of iNOS as well
as eNOS, was clearly associated with impaired healing
Figure 5
Upregulation of nNOS mRNA by ErbB receptor ligands in HaCaT
cells. Quiescent human HaCaT keratinocytes were stimulated with
EGF, heparin-binding EGF (HB-EGF), heregulin (H)-a, H-b1, or
transforming growth factor-a (TGF-a) (100 ng per mL) for 18 h as
indicated. RNase protection assay to detect nNOS-specific mRNA was
performed. Ctrl, non-stimulated cells. A quantification of nNOS mRNA
(x-fold induction compared with control) is shown. , po0.01
(ANOVA) compared with control. Bars indicate the mean  SD
obtained from four independent cell culture experiments. nNOS,
neuronal nitric oxide synthase.
Figure 4
Human HaCaT keratinocytes increase nNOS expression upon EGF treatment. (a) Quiescent human HaCaT keratinocytes were stimulated with
EGF (100 ng per mL) for 24 h. RNase protection assay to detect nNOS-, eNOS-, or iNOS-specific mRNA was performed as indicated. Ctrl, non-
stimulated cells. One representative experiment is shown. b-actin expression is shown as a loading control within the same gel. A quantification of
nNOS mRNA (x-fold induction compared with control) over a time period of 24 h as indicated is shown in (b). , po0.05; , po0.01 (ANOVA)
compared with control. Bars indicate the mean  SD obtained from four independent cell culture experiments. (c) Quiescent HaCaT keratinocytes
were treated with increasing amounts of EGF for 18 h as indicated. A quantification of nNOS mRNA (x-fold induction compared with control) is
shown. , po0.01 (ANOVA) compared with control. Bars indicate the mean  SD obtained from four independent cell culture experiments. (d)
Total protein (100 mg) from quiescent and EGF-treated (100 ng per mL) HaCaT cells was analyzed for nNOS-specific protein by immunoblot as
indicated. Lysate from porcine cerebellum was used to control specificity of the anti-nNOS antiserum. b-tubulin was used as a loading control. One
representative experiment is shown. nNOS, neuronal nitric oxide synthase; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide
synthase; EGF, epidermal growth factor.
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conditions in diabetic mice (Stallmeyer et al, 2002; Ka¨mpfer
et al, 2003). To close the gap of non-available data con-
cerning a potential presence of the third NOS isoform in skin
repair, we focussed on nNOS expression in skin tissue.
First, our data confirmed previous data that had shown
the presence of nNOS in skin-derived cell types such
as keratinocytes and melanocytes (Baudouin et al, 1996;
Romero-Graillet et al, 1996;Ormerod et al, 1998). In line with
these findings, we could find a constitutively expressed
nNOS in normal skin of mice. Moreover, we detected a
particularly strong expression of nNOS in wound margin
keratinocytes after wounding. Interestingly, nNOS protein
expression peaked in late stages of repair, although its
mRNA was induced more rapidly. This finding strongly
argues for a stable nNOS mRNA species that is character-
ized by a long mRNA half-life even in dynamic processes
such as wound healing. Fo¨rstermann et al (1998) showed
that constitutive expression of nNOS is associated with a
long half-life of its mRNA. In contrast, short message half-
life was observed for the inducible isoform. This finding is
further supported by the considerable stability of nNOS
mRNA in HaCaT cells shown in this study. From our data, it
is reasonable to suggest a delayed translation of stable
nNOS mRNA molecules that might be induced by mediators
during the inflammatory phase of repair, into protein during
late repair. Interestingly, cell culture experiments demon-
strated that induction of nNOS was restricted to an
activation of the EGFR; however, especially the potent
EGFR ligands EGF and TGF-a are well known to be pre-
sent during the inflammatory phase of repair (Martin, 1997;
Singer and Clark, 1999). Interestingly, published data
demonstrated that the iNOS isoform is expressed during
wound inflammation and represents the predominant
source of NO that finally drives tissue regeneration (Frank
et al, 1998a, 1999; Yamasaki et al, 1998). By contrast, nNOS
protein levels were markedly increased when wound
inflammation had declined, suggesting a potential role for
nNOS-derived NO in keratinocyte proliferation rather than
inflammation. Evidently, here we describe an additional
situation where an initially considered ‘constitutively’ ex-
pressed gene is indeed regulated (Fo¨rstermann et al, 1998).
Figure 6
Expression of activated epidermal growth factor receptor (EGFR)
at the wound site. (a) Total protein (50 mg) from non-wounded (ctrl skin)
and wounded skin was analyzed for the presence of phosphorylated
(Y1173) EGFR-specific protein by immunoblot as indicated. One
representative experiment is shown. Frozen sections from mouse
wounds isolated at day 5 (b) and day 7 (c) post-wounding were
incubated with a polyclonal antiserum directed against phosphorylated
(Y1173) EGFR. Sections were subsequently stained with the avidin–
biotin–peroxidase complex system using 3,3-diaminobenzidine tetra-
hydrochloride as a chromogenic substrate. Nuclei were counterstained
with hematoxylin. Immunopositive signals within the sections are
indicated with arrows. d, dermis; e, epidermis.
Figure7
EGFR antagonists inhibit nNOS mRNA expression in HaCaT cells.
Quiescent HaCaT keratinocytes were treated with EGF (100 ng per mL)
in the presence or absence of increasing amounts of the EGFR
antagonist PD153035 (a) or the EGFR/JAK2/3 inhibitor AG490 (b) for
24 h as indicated. RNase protection assay to detect nNOS-specific
mRNA was performed. A quantification of nNOS mRNA (x-fold
induction compared with control) is shown. , po0.01 (ANOVA)
compared with control. Bars indicate the mean  SD obtained from
four independent cell culture experiments (n¼4). EGFR, epidermal
growth factor receptor; nNOS, neuronal nitric oxide synthase.
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EGF represents a potent mitogen for epithelial cells and
EGF is known to contribute to re-epithelialization processes
during wound healing (Nanney, 1990). Moreover, expression
of the EGFR is elevated in repair (Stoscheck et al, 1992).
Here we found a transient increase in activated EGFR
during the inflammatory and proliferative phase of repair,
clearly matching the observed induction of nNOS mRNA
after wounding. Interestingly, from all mediators tested, only
ligands of the EGFR family were able to increase basal
nNOS expression in HaCaT keratinocytes. More important,
EGF stimulation was specific for nNOS, as eNOS and iNOS
messages were not detectable in basal or EGF-induced
conditions. Nevertheless, at least iNOS could be strongly
induced by cytokines in the cells (Frank et al, 1998b). EGFR
is able to heterodimerize with three additional members of
the EGFR familiy (ErbB). In combination with ErbB2–ErbB4,
receptor heterodimerization allows signaling from additional
ligands such as HB-EGF, heregulin-a or heregulin-b1 (Yard-
en and Sliwkowski, 2001). In line, a formation of homo-
and heterodimers between the ErbB tyrosine kinases has
been demonstrated in HaCaT cells (Marques et al, 1999).
Interestingly, the PDZ domain of ErbB4 interacts with a
complex containing nNOS (Garcia et al, 2000; Huang et al,
2000). Heregulin-b1 was shown to upregulate nNOS
expression (Krainock and Murphy, 2001b) in neuronal cells;
however, in contrast to keratinocytes, upregulation of nNOS
in neurons by heregulin-b1 was dependent on activation of
the MAPK pathway in the cells (Krainock and Murphy,
2001a), indicating that activation of different signaling
routes from ErbB receptors might be cell-type specific.
Additional data demonstrated that EGF did not stimulate
the respective nNOS promoter activity, but increased the
stability of nNOS mRNA (data not shown).
In summary, our study suggests that nNOS is constitu-
tively expressed in normal skin tissue, and induced in late
phases of skin repair. Keratinoyctes were the predominant
nNOS expressing cell type at the wound site, and in vitro
experiments revealed EGF as a potent inducer of nNOS
expression in the cells. Thus, it is reasonable to suggest
that, besides the iNOS and eNOS isoforms, also nNOS
enzymatic activity might contribute to a functional NO
production in wound tissue.
Materials and Methods
Wounding and preparation of wound tissues BALB/c mice
were obtained from Charles River (Sulzfeld, Germany) and
maintained under a 12-h-light/12-h-dark cycle at 221C until they
were 8 wk of age. At this time they were caged individually and
wounded as previously described (Frank et al, 1999). Briefly, six
full-thickness wounds were created on each animal, and skin
biopsy specimens were taken 1, 3, 5, 7, and 14 d after injury. For
every experimental time point, the wounds from four animals and
the non-wounded back skin from four animals were combined and
used for RNA and protein isolation, respectively. All animal
experiments were carried out according to the guidelines and with
the permission of the local government of Hessen, Germany.
Cell culture The human keratinocyte cell line HaCaT (Boukamp
et al, 1988) was kindly provided by Dr N. E. Fusenig, German
Cancer Research Center (DKFZ), Heidelberg, Germany. HaCaT
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
with 10% fetal bovine serum (FCS), 2 mmol per liter L-glutamine,
and 1% penicillin/streptomycin. Under these culture conditions,
the HaCaT cells remain proliferative and undifferentiated. Before
treatment with various EGFR ligands (f.c. 100 ng per mL), the cells
were grown to confluency without changing the medium and
rendered quiescent by a 24 h incubation in serum-free DMEM.
Human primary epidermal keratinocytes were purchased from
BioWhittaker Europe Inc. (Verviers, Belgium) and cultured in a
defined keratinocyte medium (KBM-2) according to the instruc-
tions of the supplier. All cells were maintained at 371C in 10% CO2.
DMEM, FCS and cell culture reagents were from Invitrogen/GIBCO
(Groningen, The Netherlands).
Reverse transcription- (RT-) PCR and RT-real time-PCR Re-
verse transcription (RT) was performed using 2 mg total RNA
purified from various human tissues, primary keratinocytes and
HaCaT cells as template, a combination of oligo(dT)1218 and
random hexamers as primers and Superscript reverse transcrip-
tase (Invitrogen, Groningen, The Netherlands). The obtained
cDNAs served as templates in PCR using Expand polymerase
(Roche Diagnostics, Mannheim, Germany). For detection of nNOS
expression, the oligonucleotides: 50-CTT CAA GAA GCT AGC AGA
AGC TGT-30 and 50-ACA AGG ACC AGA GTT TCA TGT TC-30 were
used as sense and antisense primers, respectively. Sequencing of
the 222 nucleotide PCR product demonstrated the amplification of
nNOS mRNA (end of exon 13, exon 14, part of exon 15, EMBL Acc.
No. NM_000620). For the analysis of the various EGFR receptors
subtypes, the following primer pairs were used: 50-ACT CCT TCA
CAC ATA CTC CTC CTC-30 and 50-CAT CTC CAT CAC TTA TCT
CCT TGA-30 (for EGFR, EMBL Acc. No. XXX), 50-GAC ATT GAC
GAG ACA GAG TAC CAT-30 and 50-CAT GTA GAC ATC AAT GGT
GCA GAT-30 (for ErbB2, EMBL Acc. No. X03363), 50-ACC AGA CAC
TGT ACA AGC TCT ACG-30 and 50-GCT GGA GTT GGT GTT ATA
GTT CAA-30 (for ErbB3, EMBL Acc. No. M34309) or 50-GCA AAG
TAC ACA TAT GGA GCA TTC-30and 50-ATT CCC ATT GAT CTT GGT
ACA GTT-30 (for ErbB4, EMBL Acc. No. L07868).
nNOS message in non-wounded and wounded skin of mice
was quantified by real time (RT) PCR using the iCyler (BioRad,
Munich, Germany). One step RT-PCR was performed on 500 ng of
total RNA isolated from biopsies using the QuantiTect Probe RT-
PCR mix (Qiagen, Milden, Germany). For detection of murine nNOS
expression, the oligonucleotides 50-GGT GGA GAT TAA CAT TGC
TGT CC TA-30 and 50-TTC TCC ATG TGT TTG ATG AAG GAC T-30
were used as primers, and 50-6FAM-ACA GCT TCC AGA GTG ACA
AGG TGA CCA TTG-TAMRA served as the fluorescent TaqMan
probe. Levels of nNOS were normalized by amplification of the
murine constitutive porphobilinogen deaminase (PBGD) mRNA
(50-CCC TGG CAT ACA GTT TGA AAT CA-30 and 50-AGG AGG TAG
TAT GGT AGG CAC ATC C-30 as primers and 50-6 JOE-ACC AAG
GAG CTA GAA AAC GCC CTG GA-TAMRA-30 as Taqman probe).
Fluorescence was monitored at each cycle during the annealing/
extension step.
RNA isolation and ribonuclease protection assays Total cellular
RNA was isolated as described previously (Chomczynski and
Sacchi, 1987). The plasmids containing cDNAs for human nNOS
(Boissel et al, 2003), for human eNOS (Kleinert et al, 1998), for
iNOS (Kleinert et al, 1996), and for b-actin (Gra¨f et al, 2001) have
been described previously. Expression levels of different mRNAs
species were determined from total cellular RNA by RNase
protection assay as described (Kleinert et al, 1998; Wallerath et
al, 1999). Briefly, an antisense transcript was synthesized in vitro
using T3 or T7 RNA polymerase and [a-32P]UTP (800 Ci per mmol).
RNA samples were hybridized at 421C overnight with 100,000 cpm
of the labeled antisense transcript. Hybrids were digested with
RNases A and T1 for 1 h at 301C. Under these conditions, every
single mismatch is recognized by the RNases. Protected fragments
were separated on 5% acrylamide/8 M urea gels and analyzed
using a Phospho-Imager (BioRad, Munich, Germany). Values of
protected bands were normalized using the corresponding b-actin
bands. RNases A and T1 were from Roche Diagnostics.
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Histological analysis Mice were wounded as described above.
Animals were euthanized at days 5 and 7 after injury. Complete
wounds were isolated from the back, bisected, and frozen in
tissue-freezing medium. Six-micrometer frozen sections were fixed
with acetone and treated for 10 min at room temperature with 1%
H2O2 in PBS to inactivate endogenous peroxidases. Sections were
subsequently incubated for 60 min at room temperature with a
rabbit polyclonal antiserum recognizing the murine nNOS protein
and tyrosine-phosphorylated EGFR (Y1173) (Santa Cruz Biotech-
nology Inc., Heidelberg, Germany).
Preparation of protein lysates and western blot analysis Skin
and cell culture samples were homogenized in lysis buffer (1%
Triton X-100, 20 mM Tris/HCl, pH 8.0, 137 mM NaCl, 10% glycerol,
5 mM ethylendiaminetetraacetic acid, 1 mM phenylmethylsulfonyl
fluoride, 1% aprotinin, 15 mg per mL leupeptin). The extracts were
cleared by centrifugation (Ka¨mpfer et al, 1999; Stallmeyer et al,
1999). Fifty micrograms of total protein from skin or cellular lysates
was separated using SDS-gel electrophoresis. After transfer to
a polyvinylidene difluoride (PVDF) membrane, murine nNOS and
tyrosine (Y1173)-phosphorylated EGFR protein were detected
using the polyclonal antisera (Santa Cruz Biotechnology Inc.,
Heidelberg, Germany). To assure equal loading, Ponceau red
staining was performed. For detection of human nNOS protein in
HaCaT keratinocyte lysates, a mouse monoclonal antibody was
used (BD Transduction Laboratories, Heidelberg, Germany). As
a loading control, blots were probed with a mouse monoclonal
antibody against b-tubulin (Sigma, Deisenhofen, Germany). A
secondary antibody coupled to horseradish peroxidase and the
ECL detection system were used to visualize the nNOS and
phosphorylated EGFR proteins, respectively. Phenylmethylsufonyl
fluoride, aprotinin, and leupeptin were from Sigma (Deisenhofen,
Germany) or Roche Diagnotics (Mannheim, Germany). The ECL
detection system was obtained from Amersham (Freiburg,
Germany).
Statistics Data are shown as means  SD. Data analysis was
carried out using the unpaired Student’s t test with raw data.
Statistical comparison between more than two groups was carried
out by ANOVA and Fisher’s protected least-significant-difference
(PLSD) test.
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